Trial results for Dravet drug spurs stock surge at Bedford biotech
Stoke Therapeutics, which develops RNA-altering drugs for rare diseases, announced what it called “landmark” results from an early-stage trial of a drug for a rare, debilitating form of epilepsy that affects children.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
More News: Biotechnology | Children | Epilepsy | Health Management | Pharmaceuticals | Rare Diseases